Skip to main content

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.14
-3.05 (-1.35%)
AAPL  273.56
-4.72 (-1.70%)
AMD  209.53
-1.25 (-0.59%)
BAC  55.52
+0.38 (0.68%)
GOOG  309.35
-1.17 (-0.38%)
META  651.35
+7.12 (1.11%)
MSFT  474.24
-4.29 (-0.90%)
NVDA  176.74
+1.72 (0.98%)
ORCL  184.86
-5.11 (-2.69%)
TSLA  478.20
+19.24 (4.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.